- Home
- SY vs TLSI Comparison
SY vs TLSI Comparison
Compare SY & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SY | TLSI |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 244.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | SY | TLSI |
|---|---|---|
| Price | $2.63 | $5.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.50 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 552.0K | 200.3K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,132,009.00 | $40,207,000.00 |
| Revenue This Year | $6.36 | $55.06 |
| Revenue Next Year | $57.24 | $46.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $0.67 | $3.42 |
| 52 Week High | $6.28 | $7.95 |
Technical Indicators
Market Signals| Indicator | SY | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 38.48 |
| Support Level | $2.46 | $5.60 |
| Resistance Level | $3.00 | $7.20 |
| Average True Range (ATR) | 0.15 | 0.48 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 34.55 | 7.66 |
Price Performance
Historical ComparisonAbout SY So-Young International Inc. American Depository Shares
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.